<DOC>
	<DOC>NCT00724971</DOC>
	<brief_summary>To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in combination with Rituximab in patients with B-Cell Non-Hodgkin's lymphoma (NHL).</brief_summary>
	<brief_title>Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>CD20 and CD22positive, Bcell NHL which has progressed after 1 or 2 prior therapies. Prior therapy must have contained at least one dose of Rituximab therapy. Patients can not be refractory to Rituximab (refractory = PD under treatment or within 6 month Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1. Patients must not have received previous radioimmunotherapy. Patients tolerant to Rituximab. Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 28 days before first dose of test article. Candidate for potentially curative therapies Subjects must not have received previous radioimmunotherapy. Subjects with autologous hematopoietic stem cell transplant within the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>B-cell Non-Hodgkin's Lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>